---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-019151"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:31:56.355985+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL

## Summary
- Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.
- Cash and equivalents $7.4M as of March 31, 2025; additional $11M available under lines of credit; runway through August 2025.
- Belapectin 2 mg/kg showed statistically significant reduction in liver stiffness from baseline at weeks 26, 52, 78 (p<0.02).
- Proportion of patients with >30% worsening in liver stiffness: 11.7% for belapectin vs 23.9% for placebo (51% fewer, p=0.03).
- Data presented at EASL May 2025; Fast Track Designation for belapectin in MASH cirrhosis.

## SEC filing metadata
- accession: 0001140361-25-019151
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/0001140361-25-019151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/ef20048561_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-019151
- JSON: https://secwatch.observer/filing/0001140361-25-019151.json
- Plain text: https://secwatch.observer/filing/0001140361-25-019151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.